Objective To characterise the risk of subsequent primary non-keratinocyte skin cancers (NKSCs) among adult-onset cancer survivors. Design Data analysis of this population-based cohort study was ...

Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Seer Inc. (SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that Panome Bio has joined ...

REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER) (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, will showcase the ...

Seer, Inc. will present innovative findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia from February 22-26, 2025, where they will highlight advancements in ...

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature ...

At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...